

## Kaiser Permanente Health Plan of Mid-Atlantic States, Inc. XIFAXAN (Rifaximin) Prior Authorization (PA) Pharmacy Benefits Prior Authorization Help Desk

## Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage **XIFAXAN** (**Rifaximin**). <u>Please complete all sections, incomplete forms will delay processing.</u> <u>Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104</u>. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.** 

KP-MAS Formulary can be found at: <a href="Pharmacy">Pharmacy</a> | Community Provider Portal | Kaiser Permanente</a>

## **Length of Authorization:**

Sig:

- Initial: 12 months for Hepatic Encephalopathy; Continuation: 12 months
- Irritable Bowel Syndrome with diarrhea-14 days (one-time)
- *C. difficile* associated diarrhea -1 month (one-time)
- Traveler's diarrhea-3 days (one-time)
- Small Intestinal Bacterial Overgrowth-14 days (2 treatment courses per year)

1 - Patient Information				
Patient Name:	Kaiser Medical ID#:	Date of Birth:		
2 – Prescriber Information				
Prescriber Name:	Specialty:	NPI:		
Prescriber Address:				
Prescriber Phone #:	Prescriber Fax #:			
Do you have an approved provider referral number from Kaiser Permanente?  □ Yes – please provide your provider referral number here:				
3 – Pharmacy Information				
Pharmacy Name:	Pharmacy NPI:			
Pharmacy Phone #	Pharmacy Fax #:			
4 – Drug Therapy Requested				
Sig:				
Drug 2: Name/Strength/Formulation:				

## 5- Diagnosis/Clinical Criteria

1.	Is this request for initial or continuing therapy?  □ Initial therapy □ Continuing therapy, State date:		
2.	Indicate the Member's diagnosis for the requested medication:		
Clinical Criteria:  Is the medication being prescribed by an Infectious Disease Specialist, a Gastroenterologist, OR if prescribing for hepatic encephalopathy, may be prescribed in consultation with Gastroenterology?  □ No □ Yes			
	patic Encephalopathy:  Does the patient have a diagnosis of hepatic encephalopathy?  □ No □ Yes		
2.	Is the patient ≥18 years of age?  □ No □ Yes		
3.	Is Xifaxan (rifaximin) being used as add-on therapy to lactulose? $\hfill\Box$ No $\hfill\Box$ Yes		
4.	Has the patient been unable to achieve an optimal response with lactulose monotherapy after receiving an adequate trial, OR does patient have intolerance or contraindication to lactulose? $\Box$ No $\Box$ Yes		
<ul> <li>Irritable Bowel Syndrome with diarrhea:</li> <li>1. Does the patient have a diagnosis of irritable bowel syndrome diarrhea predominant (IBS-D)?</li> <li>□ No □ Yes</li> </ul>			
2.	Has the patient had inadequate response (must try for the minimum duration listed before considered treatment failure), contraindication or intolerance to at least TWO of the following medications?  • Loperamide - at least 2 weeks  • Diphenoxylate-atropine (Lomotil) - at least 2 weeks  • A bile acid sequestrant (e.g., cholestyramine, colestipol) - at least 2 weeks  • Dicyclomine (generic Bentyl) - at least 2 weeks  • At least one tricyclic antidepressant - at least 6 weeks  □ No □ Yes		
3.	Has the patient received $>$ 3 total treatments with rifaximin for IBS-D within the past 12 months (maximum 3 treatments with rifaximin per year)? $\Box$ No $\Box$ Yes		
	difficile:  Does the patient have a diagnosis of third recurrence of <i>C. difficile</i> associated diarrhea?  □ No □ Yes		
2.	Has the patient failed treatment with metronidazole and vancomycin for previous episodes? $\hfill\Box$ No $\hfill\Box$ Yes		

Travele	er's Diarrhea:				
1. Do	pes the patient have a diagnosis of Traveler's Diarrhea?				
	□ No □ Yes				
2. Is t	the patient intolerant or unable to take a fluoroquinolone?				
	□ No □ Yes				
3. Is t	the patient intolerant or allergic to azithromycin?				
	□ No □ Yes				
S <u>mall I</u>	Intestinal Bacterial Overgrowth (SIBO)				
	pes the patient have a diagnosis of small intestinal bacterial overgrowth (SIBO)?				
•	□ No □ Yes				
2. Ha	as the patient experienced treatment failure with at least <b>ONE</b> of the following?				
	Amoxicillin-clavulanate				
	Ciprofloxacin				
	Trimethoprim-sulfamethoxazole				
	Metronidazole				
	Doxycycline				
	Tetracycline     No    Ves				
	□ No □ Yes				
For continuation of therapy (hepatic encephalopathy indication ONLY), please respond to <u>additional questions</u> below:  Hepatic Encephalopathy:  Does the patient have a diagnosis of hepatic encephalopathy?  No Pes					
2. Is t	there documentation of a clinically significant benefit from medication? □ No □ Yes				
^ dditi(	6 – Prescriber Sign-Off ional Information –				
	ional Information – Please submit chart notes/medical records for the patient that are applicable to thi	in request			
	rlease submit chart notes/medical records for the patient that are applicable to the figure for	•			
		• • • •			
111	nformation that should be taken into consideration for the requested medication:	j.			
	I certify that the information provided is accurate. Supporting documentation is available for State audits.				
Prescr	riber Signature:	Date:			
	The state of the s	The deformation in			
	Note: This document contains confidential information, including protected health information, intended for a spect and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that a				

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Prior Authorization Form
Revision date: 7/16/2024; Effective date: 8/13/2024

any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility